Dublin, Ireland-based Allergan entered a research, development, collaboration and license agreement to develop Indianapolis’s Assembly Biosciences microbiome gastrointestinal development programs.
To combat its $30 billion debt, Lovell, Canada-based Valeant Pharmaceuticals is selling its Dendreon cancer business and three of its skincare brands for $2.12 billion.
Valeant Pharmaceuticals’ board of directors elected Richard DeSchutter director.
Madison, Wis.-based Exact Sciences — the makers of Cologuard — anticipates revenue between $34.9 and $25.4 million for the fourth quarter of fiscal year 2016.
Blue Cross Blue Shield Association’s Center for Clinical Effectiveness positively reviewed Madison, Wis.-based Exact Sciences’ Cologuard, a fecal-based colonoscopy alternative.
Japan’s Takeda Pharmaceuticals and San Diego’s PvP Biologics are developing KumaMax, a novel enzyme that breaks down immune-reactive parts of gluten in the stomach, for patients with Celiac disease.
More articles on gastroenterology and endoscopy:
Dr. J. Calvin Coffey urges classification of new abdominal organ: 5 things to know
Cancer screening, but not colonoscopy, rates increase under ACA: 4 study insights
Which lifestyle factors are associated with serrated colorectal polyps? 5 study insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
